Capstone Headwaters Advised Concord Biosciences on its Sale to Frontage Laboratories

May 2, 2018

NEW YORK, NY - Capstone Headwaters advised Concord Biosciences, LLC, in the sale of the company to Frontage Laboratories, Inc., Exton, Pennsylvania and Shanghai, PRC.  Concord is a leading contract research organization (CRO) that provides pre-clinical drug safety and metabolism, bioanalytical and agrichemical services.  It operates from its 87,000 square foot GLP-compliant facility located on 20 acres in Concord, Ohio and traces its founding to 1961.

The company’s drug safety and metabolism services include IND strategy/design, lead optimization/pharmacodynamics, exploratory pharmacokinetics, toxicology, pharmacology/genotoxicity, radiochemistry and associated support services.  Concord provides a comprehensive, integrated suite of services help clients meet their regulatory requirements and internal research, development and safety goals.

Read More